Mounjaro (tirzepatide) is a dual GLP-1 and GIP receptor agonist licensed in the UK for type 2 diabetes mellitus. Many patients wonder whether red wine and Mounjaro can be safely combined. Whilst there is no absolute contraindication to drinking red wine whilst taking Mounjaro, both alcohol and tirzepatide can independently affect blood glucose levels and gastrointestinal function. Understanding the potential risks—including hypoglycaemia, worsening nausea, and pancreatitis—is essential. This article explores the evidence, safety considerations, and practical guidance for patients prescribed Mounjaro who wish to consume red wine, in line with UK clinical guidance from NICE, the MHRA, and NHS recommendations.
Quick Answer: There is no absolute contraindication to drinking red wine whilst taking Mounjaro, but both can affect blood glucose and gastrointestinal function, requiring caution and individualised clinical advice.
Mounjaro (tirzepatide) is a glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus. Many patients prescribed Mounjaro wonder whether they can safely consume red wine or other alcoholic beverages during treatment.
There is no absolute contraindication to drinking red wine whilst taking Mounjaro. The Summary of Product Characteristics (SmPC) approved by the Medicines and Healthcare products Regulatory Agency (MHRA) does not list alcohol as a formal contraindication. However, this does not mean that alcohol consumption is without risk for patients on this medication.
The key consideration is that both Mounjaro and alcohol can independently affect blood glucose levels and gastrointestinal function. Mounjaro works by enhancing insulin secretion in a glucose-dependent manner, slowing gastric emptying, and reducing appetite. Alcohol, particularly when consumed without food, can cause hypoglycaemia (low blood sugar) and may exacerbate some of the gastrointestinal side effects commonly associated with Mounjaro, such as nausea, vomiting, and abdominal discomfort.
Patients should discuss alcohol consumption with their GP or diabetes specialist nurse before drinking red wine regularly whilst on Mounjaro. Individual factors—including overall diabetes control, other medications (particularly insulin or sulphonylureas), liver function, and personal tolerance—will influence whether moderate alcohol consumption is appropriate. The SmPC notes that dose reduction of insulin or sulphonylureas may be needed to reduce hypoglycaemia risk when used with Mounjaro. The decision should be personalised and based on a thorough clinical assessment.
Mounjaro® is the most innovative GLP-1 medication proven to dramatically curb appetite, hunger, and cravings to help professional men achieve substantial weight loss.
Start Here
Wegovy® is a weekly injectable GLP-1 medication with proven effectiveness in reducing appetite, hunger, and cravings to help busy professionals lose significant weight.
Start HereUnderstanding the interaction between alcohol and blood glucose regulation is essential for patients taking Mounjaro. Alcohol metabolism occurs primarily in the liver, which is also responsible for glucose production (gluconeogenesis) and glucose storage (glycogenolysis). When the liver is occupied metabolising alcohol, its ability to release glucose into the bloodstream is impaired.
In people with diabetes, this can lead to delayed hypoglycaemia—low blood sugar that may occur several hours after drinking, sometimes during sleep. This risk is heightened when alcohol is consumed on an empty stomach or in large quantities. Mounjaro itself does not typically cause hypoglycaemia when used as monotherapy because its insulin-releasing effect is glucose-dependent. However, when combined with alcohol, the risk of low blood sugar increases, particularly if the patient is also taking other glucose-lowering medications such as insulin or sulphonylureas.
Red wine contains approximately 10–14% alcohol by volume and also includes small amounts of carbohydrates (around 2–4 grams per 175 ml glass). While the carbohydrate content may cause a modest initial rise in blood glucose, the overall effect of alcohol tends to be hypoglycaemic, especially in the hours following consumption.
Important cautions for specific medications:
Metformin: Heavy alcohol consumption while taking metformin increases the risk of lactic acidosis, a rare but serious condition.
SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin): Alcohol can increase the risk of dehydration, which, combined with these medications, may precipitate diabetic ketoacidosis (DKA), sometimes with near-normal blood glucose levels.
Patients should be advised to:
Monitor blood glucose levels more frequently when consuming alcohol
Never drink on an empty stomach—always consume alcohol with a meal or carbohydrate-containing snack
Be aware of delayed hypoglycaemia, particularly overnight
Recognise symptoms of low blood sugar: sweating, tremor, confusion, palpitations, and hunger
Seek urgent medical advice if feeling unwell, particularly if taking SGLT2 inhibitors
Regular alcohol consumption can also impair overall glycaemic control and may interfere with weight management goals, which are often a key therapeutic target in patients prescribed Mounjaro.
Beyond the effects on blood glucose, there are several additional risks associated with combining red wine and Mounjaro that patients and clinicians should consider.
Gastrointestinal side effects are among the most common adverse reactions to Mounjaro, particularly during the initial weeks of treatment or following dose escalation. These include nausea, vomiting, diarrhoea, abdominal pain, and reduced appetite. Alcohol is a known gastric irritant and can exacerbate these symptoms. Red wine, in particular, is acidic and may worsen nausea or gastro-oesophageal reflux. Patients who already experience significant gastrointestinal upset with Mounjaro may find that even small amounts of alcohol intensify these effects.
Acute pancreatitis has been reported with tirzepatide use. Excessive alcohol consumption is an independent risk factor for both acute and chronic pancreatitis. While there is no official evidence that moderate red wine consumption directly increases pancreatitis risk in Mounjaro users, patients should be aware of this potential risk. Symptoms of pancreatitis—severe, persistent abdominal pain radiating to the back, nausea, and vomiting—require urgent medical assessment. If pancreatitis is suspected, stop taking Mounjaro immediately and call 999 or attend A&E.
Dehydration is another concern. Both alcohol and Mounjaro-related gastrointestinal symptoms (vomiting, diarrhoea) can lead to fluid loss. Dehydration may worsen side effects and impair renal function, potentially leading to acute kidney injury, particularly in older adults or those with pre-existing kidney disease.
Caloric intake and weight management: Red wine contains approximately 120–130 calories per 175 ml glass, according to NHS guidance. For patients using Mounjaro as part of a weight management strategy, regular alcohol consumption can undermine weight loss efforts. Alcohol also lowers inhibitions and may lead to poor dietary choices.
Suspected adverse reactions to Mounjaro should be reported via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk).
If a patient on Mounjaro chooses to drink red wine, adherence to UK Chief Medical Officers' low-risk drinking guidelines is essential. These recommend that both men and women should not regularly drink more than 14 units of alcohol per week. This should be spread over three or more days, with several alcohol-free days each week. A standard 175 ml glass of red wine (12% ABV) contains approximately 2.1 units of alcohol.
Practical safety measures for Mounjaro users include:
Limit intake: Stick to one or two small glasses of red wine on any single occasion, and avoid daily drinking.
Always eat: Consume alcohol only with or after a meal containing carbohydrates to reduce hypoglycaemia risk.
Monitor blood glucose: Check levels before drinking, two hours after, and before bed. Consider setting an alarm to check overnight if you have consumed more than usual.
Stay hydrated: Alternate alcoholic drinks with water to maintain hydration and reduce gastrointestinal irritation.
Avoid binge drinking: Large quantities of alcohol significantly increase the risk of hypoglycaemia, dehydration, and acute pancreatitis.
Inform companions: Ensure someone knows you have diabetes and can recognise signs of hypoglycaemia, which can be mistaken for intoxication.
Carry glucose: Always have fast-acting carbohydrate (glucose tablets, sugary drink) available in case of low blood sugar.
Consider a bedtime snack containing carbohydrate if you've been drinking in the evening.
Never adjust insulin doses to accommodate alcohol without specific advice from your diabetes care team.
Patients should also be aware that alcohol can impair judgement and the ability to recognise hypoglycaemia symptoms. If in doubt, it is safer to abstain, particularly during the initial titration phase of Mounjaro when side effects are most pronounced.
There are specific circumstances in which patients taking Mounjaro should avoid alcohol entirely or exercise extreme caution.
During the initial titration period: The first few weeks of Mounjaro treatment, and each time the dose is increased, are associated with the highest incidence of gastrointestinal side effects. Avoiding alcohol during these periods can help minimise nausea, vomiting, and abdominal discomfort, allowing the body to adjust to the medication.
If taking other glucose-lowering medications: Patients on combination therapy—particularly those using insulin, sulphonylureas (e.g., gliclazide), or meglitinides—face a substantially higher risk of hypoglycaemia when consuming alcohol. These patients should discuss alcohol use carefully with their diabetes care team and may need to adjust medication doses.
History of pancreatitis: Patients with a history of pancreatitis should seek specialist advice regarding alcohol consumption. Those with previous alcohol-related pancreatitis should abstain completely. The Mounjaro SmPC advises caution when using tirzepatide in patients with a history of pancreatitis.
Liver disease: Patients with hepatic impairment should seek individualised advice from their clinician regarding alcohol consumption. Those with alcohol-related liver disease or advanced liver disease should generally abstain, while those with mild fatty liver may be advised to limit intake, depending on clinical assessment.
Pregnancy and breastfeeding: Alcohol should be avoided entirely during pregnancy and breastfeeding. Mounjaro is not recommended during pregnancy, and effective contraception should be used.
Severe gastrointestinal symptoms: If experiencing persistent nausea, vomiting, or diarrhoea, alcohol will likely worsen symptoms and increase dehydration risk.
When to seek medical help:
Call 999 or attend A&E: For severe, persistent abdominal pain (especially if radiating to the back), persistent vomiting, or signs of acute illness
Contact your GP: For recurrent hypoglycaemia (blood glucose <4 mmol/L), signs of dehydration (dark urine, dizziness, reduced urine output), or concerns about alcohol use or diabetes control
Call NHS 111: For urgent advice when your GP is unavailable
Patients should be empowered to make informed decisions about alcohol consumption in consultation with their healthcare team, prioritising safety and optimal diabetes management.
There is no absolute contraindication to drinking red wine whilst taking Mounjaro, but both can affect blood glucose and gastrointestinal function. Patients should discuss alcohol consumption with their GP or diabetes specialist nurse and adhere to UK low-risk drinking guidelines.
Yes, alcohol can impair the liver's ability to release glucose, increasing the risk of delayed hypoglycaemia, particularly when Mounjaro is combined with insulin or sulphonylureas. Always consume alcohol with food and monitor blood glucose levels closely.
Avoid alcohol during the initial titration period, if you have a history of pancreatitis or liver disease, if taking insulin or sulphonylureas, or if experiencing severe gastrointestinal symptoms. Seek individualised advice from your diabetes care team.
All medical content on this blog is created based on reputable, evidence-based sources and reviewed regularly for accuracy and relevance. While we strive to keep content up to date with the latest research and clinical guidelines, it is intended for general informational purposes only.
DisclaimerThis content is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional with any medical questions or concerns. Use of the information is at your own risk, and we are not responsible for any consequences resulting from its use.
